• About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng
Menu
  • About
    • Our Company
    • Contact
  • Science
    • PIKA Technology Platform
  • Pipeline
    • Our Pipeline
    • Product Candidate
      • Infectious Disease
      • Immuno-Oncology Biotherapeutics
    • Commercial Products
  • Business Development
    • Partnerships
  • Investor Relations
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Resources
      • Investor FAQs
      • Email Alerts
      • Information Request
      • Contact IR
  • Career
    • Working at Yisheng

Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors

  • May 13, 2021
  • wordpress202104
  • Press Release
BEIJING, June 26, 2019 /PRNewswire/ Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that...
Continue Reading

Yisheng Biopharma Receives GMP Certification from China NMPA for Production of Lyophilized Rabies Vaccine for Preventive Use

  • May 5, 2021
  • wordpress202104
  • Press Release
Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, announced that its new rabies vaccine production...
Continue Reading

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

  • May 5, 2021
  • wordpress202104
  • Press Release
Yisheng Biopharma Co., Ltd. (“Yisheng Biopharma”), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, and Tavotek Biotherapeutics, a biotech company focusing...
Continue Reading

Search

Recent Posts

  • YS Biopharma Received Qualified Person Declaration for Its PIKA COVID-19 Vaccine Facility from European Union GMP
  • YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 vaccine
  • YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.
  • YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
  • A New Therapeutic Vaccine Successfully Developed Against Rabies

Recent Comments

    Archives

    • November 2022
    • September 2022
    • June 2021
    • May 2021
    • February 2021

    Categories

    • 2022
    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Site MapTerms of UsePrivacy

    Contact Info

    YS Biopharma Co., Ltd.

    11 Firstfield Road Suite A
    Gaithersburg, Maryland 20878 USA

    Tel: +1 (301) 208 8823
    Fax: +1 (301) 208 8827

    bjinfo@yishengbio.com

    Copyright © 2021 Yisheng Biopharma. All Rights Reserved.